pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioPharma Dive·May 12·1 min read
save

FDA chief Marty Makary resigns, ending turbulent tenure

May 12, 2026·read at BioPharma Dive ↗RegulatoryNegative

FDA chief Marty Makary has resigned, ending a tenure described as turbulent with leadership upheaval, mass layoffs, political pressure and public disputes with drugmakers.

President Trump announced the resignation, confirming a Politico report, and named deputy commissioner Kyle Diamantis as acting commissioner.

Makary, a prolific medical researcher and author known for work on patient safety and criticism of public health responses, was appointed by Trump in November 2024; the Department of Health and Human Services declined comment.

source

This writeup was produced by pharmadog from original reporting by BioPharma Dive.

Original headline: “FDA chief Marty Makary resigns from agency, ending tumultuous tenure”

read at BioPharma Dive ↗
697 words · retrieved May 12
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.
drugs
MIFEPRISTONE
topics
Approval2Gene Therapy (AAV)OncologyRare DiseaseVaccines

related stories

  • 4d agoGSK laying off 1.2K+ in BelgiumBioSpace
  • Sep 24US senators grill FDA nominee Overton on ability to ‘stand up’ to TrumpBioSpace
  • Sep 17FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type Afda press
  • Sep 14After a brief storm of political headwinds, mRNA is back with strong momentumBioSpace
  • Jun 29FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturingfda press